Coya Therapeutics Inc (COYA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.76+4.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Coya Therapeutics is advancing clinical-stage biotech work on regulatory T cell medicines. The company has maintained cash runway into 2027, supporting ongoing development. Recent earnings beats show some operational progress despite losses. Debt and equity raises provide funding for trials.
Coya is still loss-making with negative EPS expected through 2027. Revenue is forecast to decline about 27% next year. Capital raises dilute shareholders and signal funding risk. Clinical and regulatory setbacks could delay or derail progress.
The stock price is about 5% above our valuation model's midpoint. Analysts expect revenue to decline roughly 27% next year. Our view is cautious given ongoing losses and uncertain clinical outcomes.
Breaks if: Cash reserves fall short of sustaining operations into second half of 2027
Breaks if: EPS loss worsens beyond -$1.83 per share in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. COYA is currently loss-making, and while it has some positive momentum in clinical trials, its recent financial performance has been weak.
The market appears to have low expectations for COYA, as indicated by a significant expectations gap. Valuation is aligned with peers, but COYA trades at a premium, suggesting that investors may be cautious about its future performance.
Management is focused on advancing clinical trials and maintaining a cash runway. While recent earnings have shown positive surprises, the overall financial performance remains below industry standards, indicating potential challenges ahead.
The future of COYA depends on the outcomes of its clinical trials and the overall health of the healthcare sector. Key factors include the performance of sector leaders and any changes in guidance or economic conditions that could impact investor sentiment.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports this improvement. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue decline exceeds -10% YoY in FY27
In the next 1 to 3 years, COYA's trajectory will largely depend on its clinical advancements and sector dynamics. Not investment advice.